KRONOS BIO

At Kronos Bio, we're focused on creating a world where no life is cut short by cancer or other serious diseases. That's why we're developing therapeutics that target the dysregulated transcription that causes cancer and autoimmune diseases-to bring forward novel therapies for patients who need them... At Kronos Bio, we have three molecules that have emerged from our product engine. Istisociclib, our CDK9 inhibitor, is being evaluated in a phase 1/2 clinical trial as a treatment for patients with MYC-dependent tumors such as ovarian cancer. Our second development candidate, KB-9558, targets the KAT domain of p300, a critical node of the IRF4 TRN, which is a core oncogenic transcription program that drives multiple myeloma and HPV-driven tumors. We have a third development candidate, KB-7898, a p300 KAT inhibitor being developed for the treatment of Sjögren's disease... Our team has an established track record with decades of scientific and business experience. We find meaning in..

Also known as: Kronos Bio, Inc.

Primary location: San Mateo United States